• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe
Katie Rubanka

Katie Rubanka

Associate Attorney, Washington, D.C.

krubanka@gibsondunn.com

+1 202.777.9409

Katherine (Katie) Rubanka is a litigation associate in the Washington, D.C. office of Gibson, Dunn & Crutcher.

View Full Profile

New DEI Compliance Requirements for Federal Contractors – What Life Sciences Companies Need to Know

June 4, 2026 | Posted by Ryan A. Murr; Jonathan M. Phillips; Lindsay M. Paulin; Cynthia Chen McTernan; Emma Eisendrath; Benjamin R. Saul; Sarah-Jane Lorenzo; Katie Rubanka; Topic(s): Clinical Trials; False Claims Act; FDA; FDA Guidance; Government Regulation; Trends and Insights

Life sciences companies should be aware of a new contract clause and accompanying guidance from the Federal Acquisition Regulatory Council (“FAR Council”) implementing President Trump’s Executive Order 14398, Addressing DEI Discrimination by Federal Contractors. Effective April 24, 2026, all new Federal solicitations and contracts subject to the Federal Acquisition Regulation (“FAR”) must contain a new FAR clause requiring certification that the contractor does not engage in “racially discriminatory DEI activities,” as defined by the clause, in connection with the performance of work under the contract.  Under the guidance, agencies must also modify all existing FAR-covered contracts to include the requisite certification language by July 24, 2026, and contractors will be required to flow down the clause in their subcontracts.

Read More

Primary Sidebar

Read our Life Sciences 2026 Outlook here.
Read our 2026 Royalty Finance Market Update here.

Topics

Antitrust

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

License Agreements

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Disclosure

SEC Updates

Securities Litigation

Shareholder Activism

Tax

Trends and Insights

Editors

Rachel E. Baron

Branden C. Berns

Aaron K. Briggs

Jina L. Choi

Matt Donnelly

Emma Eisendrath

Pamela Lawrence Endreny

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Bree Gong

Charlotte Jacobsen

Candice D. Johnson

Jin Hee Kim

Zaneta J. Kim

Wynne Leahy

Nicholas G. Linke

Jeff Lombard

Sarah-Jane Lorenzo

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

Cynthia Chen McTernan

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Lindsay M. Paulin

Michael J. Perry

Jonathan M. Phillips

Ryan Rott

Katie Rubanka

Benjamin R. Saul

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Evan Shepherd

Eric B. Sloan

Adam M. Smith

Bradley P. Smith

Karen A. Spindler

Eric J. Stock

Ayushi Sutaria

Terrell Ussing

Jessica Valenzuela

Stephen Weissman

Kamia Williams

David A. Wolber

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.